While very few patients are expected to access new psychedelic therapies when regulatory changes take effect next month, medicinal cannabis companies, drug developers and health insurers are keeping watch on the emerging industry.

Medicinal cannabis companies are trying to get a foothold in Australia’s new psychedelics market, with therapies using MDMA and psilocybin to treat severe mental health conditions permitted from next…